The effect of liposomal size on the targeted delivery of doxorubicin toIntegrin αvβ3-expressing tumor endothelial cells

Biomaterials

Volumn 34, Issue 22, 2013, Pages 5617-5627

  Kibria, Golam ^a   Hatakeyama, Hiroto ^a   Ohga, Noritaka ^a   Hida, Kyoko ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Anti angiogenic effect; Drug resistant cancer; Ligand multivalency; Size of liposomes; Tumor vasculature targeting

Indexed keywords

ANTI-ANGIOGENIC ACTIVITY; ANTI-ANGIOGENIC EFFECT; CELLULAR INTERNALIZATION; DRUG-RESISTANT CANCER; ENHANCED PERMEABILITY AND RETENTION EFFECTS; LIGAND-RECEPTOR INTERACTIONS; MULTIVALENCY; TUMOR VASCULATURE TARGETING;

ENDOTHELIAL CELLS; LIGANDS; LIPOSOMES;

TUMORS;

ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; LIPOSOME; MACROGOL; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG UPTAKE; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL SHAPE; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; OLIGOPEPTIDES; ORGAN SPECIFICITY; PARTICLE SIZE; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 84877609222     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.094     Document Type: Article

References (56)

1. Slingerland M., Guchelaar H.J., Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012, 17:160-166.
2. Haley B., Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008, 26:57-64.
3. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
4. ®) liposomes in a human tumor xenografts. Cancer Res 1994, 54:3352-3356.
5. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003, 63:7400-7409.
6. Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Fuga K., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A 2008, 105:9343-9348.
7. Schiffelers R.M., Koning G.A., ten Hagen T.L., Fens M.H., Schraa A.J., Janssen A.P., et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. JControl Release 2003, 91:115-122.
8. Pastorino F., Brignole C., Marimpietri D., Sapra P., Moase E.H., Allen T.M., et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003, 63:86-92.
9. Poljaková J., Eckschlager T., Hřebačková J., Hraběta J., Stiborová M. The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells. Interdiscip Toxicol 2008, 1:186-189.
10. Park J., Bae E., Lee C., Yoon S.S., Chae Y.S., Ahn K.S., et al. RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol 2010, 31:643-650.
11. Burg M.A., Pasqualini R., Arap W., Ruoslahti E., Stallcup W.B. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 1999, 59:2869-2874.
12. Kondo M., Asai T., Katanasaka Y., Sadzuka Y., Tsukada H., Ogino K., et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004, 108:301-306.
13. Oku N., Asai T., Watanabe K., Kuromi K., Nagatsuka M., Kurohane K., et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 2002, 21:2662-2669.
14. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156:1363-1380.
15. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-743.
16. Decuzzi P., Godin B., Tanaka T., Lee S.Y., Chiappini C., Liu X., et al. Size and shape effects in the biodistribution of intravascularly injected particles. JControl Release 2010, 141:320-327.
17. Gentile F., Curcio A., Indolfi C., Ferrari M., Decuzzi P. The margination propensity of spherical particles for vascular targeting in the microcirculation. JNanobiotechnol 2008, 6:9.
18. Haun J.B., Hammer D.A. Quantifying nanoparticle adhesion mediated by specific molecular interactions. Langmuir 2008, 24:8821-8832.
19. Liu D., Mori A., Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1992, 1104:95-101.
20. Maruyama K., Yuda T., Okamoto A., Kojima S., Suginaka A., Iwatsuru M. Prolonged circulation time invivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta 1992, 1128:44-49.
21. Litzinger D.C., Buiting A.M., van Rooijen N., Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994, 1190:99-107.
22. Kibria G., Hatakeyama H., Ohga N., Hida K., Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. JControl Release 2011, 153:141-148.
23. Vogelzang N.J., Stadler W.M. Kidney cancer. Lancet 1998, 352:1691-1696.
24. Efferth T., Volm M. Protein expression profiles indicative for drug resistance of kidney carcinoma. Cancer Genomics & Proteomics 2004, 1:17-22.
25. Mourad W.F., Dutcher J., Ennis R.D. State-of-the-art management of renal cell carcinoma. Am J Clin Oncol 2012 Aug 2, [Epub ahead of print].
26. Staehler M., Rohrmann K., Bachmann A., Zaak D., Stief C.G., Siebels M. Therapeutic approaches in metastatic renal cell carcinoma. BJU Int 2005, 95:1153-1161.
27. Soto-Vega E., Arroyo C., Richaud-Patin Y., García-Carrasco M., Vázquez-Lavista L.G., Llorente L. P-glycoprotein activity in renal clear cell carcinoma. Urol Oncol 2009, 27:363-366.
28. Shimizu K., Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004, 27:599-605.
29. Hida K., Hida Y., Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008, 99:459-466.
30. Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-6295S.
31. Hutson T.E. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. The Oncologist 2011, 16:14-22.
32. Di Lorenzo G., Buonerba C., Biglietto M., Scognamiglio F., Chiurazzi B., Riccardi F., et al. The therapy of kidney cancer with biomolecular drugs. Cancer Treat Rev 2010, 36(Suppl. 3):S16-S20.
33. Zhang L., Bhasin M., Schor-Bardach R., Wang X., Collins M.P., Panka D., et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One 2011, 6:e19144.
34. Huang D., Ding Y., Zhou M., Rini B.I., Petillo D., Qian C.N., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
35. Hammers H.J., Verheul H.M., Salumbides B., Sharma R., Rudek M., Jaspers J., et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010, 9:1525-1535.
36. Di Lorenzo G., Porta C., Bellmunt J., Sternberg C., Kirkali Z., Staehler M., et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011, 59:526-540.
37. Takara K., Hatakeyama H., Kibria G., Ohga N., Hida K., Harashima H. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. JControl Release 2012, 162:225-232.
38. Matsuda K., Ohga N., Hida Y., Muraki C., Tsuchiya K., Kurosu T., et al. Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 2010, 394:947-954.
39. Akino T., Hida K., Hida Y., Tsuchiya K., Freedman D., Muraki C., et al. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009, 175:2657-2667.
40. Tsuchiya K., Hida K., Hida Y., Muraki C., Ohga N., Akino T., et al. Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol 2010, 36:1379-1386.
41. Fritze A., Hens F., Kimpfler A., Schubert R., Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta 2006, 1758:1633-1640.
42. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradient in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993, 1151:201-215.
43. Enoch H.G., Strittmatter P. Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. Proc Natl Acad Sci U S A 1979, 76:145-149.
44. Xu X., Khan M.A., Burgess D.J. Predicting hydrophilic drug encapsulation inside unilamellar liposomes. Int J Pharm 2012, 423:410-418.
45. A mathematical model to predict drug encapsulation inside liposomes. Available from URL: . http://www.liposomemodel.com.
46. Ogawara K., Un K., Tanaka K., Higaki K., Kimura T. Invivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. JControl Release 2009, 133:4-10.
47. Montet X., Funovics M., Montet-Abou K., Weissleder R., Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. JMed Chem 2006, 49:6087-6093.
48. Singh B., Rawlings N., Kaur A. Expression of integrin alphavbeta3 in pig, dog and cattle. Histol Histopathol 2001, 16:1037-1046.
49. Singh B., Fu C., Bhattacharya J. Vascular expression of the alpha(v)beta(3)-integrin in lung and other organs. Am J Physiol Lung Cell Mol Physiol 2000, 278:L217-L226.
50. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006, 66:10073-10082.
51. Wang Z., Yu Y., Dai W., Lu J., Cui J., Wu H., et al. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials 2012, 33:8451-8460.
52. Du B., Han H., Wang Z., Kuang L., Wang L., Yu L., et al. Targeted drug delivery to hepatocarcinoma invivo by phage-displayed specific binding peptide. Mol Cancer Res 2010, 8:135-144.
53. Zheng J.Y., Chen D., Chan J., Yu D., Ko E., Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther 2003, 10:764-770.
54. Dass C.R., Choong P.F. Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int 2006, 6:17.
55. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
56. Molema G., Meijer D.L., de Leij L.F. Tumor vasculature targeted therapies: getting the players organized. Biochem Pharmacol 1998, 55:1939-1945.